📊 Symrise - Financial year 2025 (Earnings)
Symrise AG has published its figures for the 2025 fiscal year. The company reported solid organic growth despite difficult conditions.
Key earnings figures 2025 (preliminary / adjusted):
- Total sales: € 4.93 billion (lower than previous year (€ 4.999 billion))
- Organic sales growth: +2.8%
- Adjusted EBITDA: € 1.081 billion
EBITDA 2024: € 1.033 billion
- Adj. EBITDA margin: 21.9% (plus 120 basis points YoY)
- Adjusted net profit: € 513 million
- Adjusted earnings per share: € 3.67
- Dividend proposal: € 1.25 per share (previous year: € 1.20) + buyback of € 400 million
- Free cash flow at record level: € 780 million
- Net debt: slightly reduced, target range
The published figures include non-cash impairments, particularly in the Terpene and Swedencare business, which reduce IFRS earnings per share to € 1.78.
📈 Outlook & strategy
Forecast for 2026: organic growth of 2.0% to 4.0%, EBITDA margin 21.5% to 22.5% and free cash flow margin >14%.
Symrise confirms its medium-term targets until 2028:
- Organic sales growth CAGR 5-7 %
- EBITDA margin 21-23 %
- Free cash flow margin >14 %
Management's key message is that the ONE SYM strategy will continue to be implemented and that profitability and cash generation have improved.
💡 Conclusion
Symrise delivered a more stable result than expected in 2025
✔ Organic growth despite market uncertainties
✔ EBITDA margin at an attractive level
✔ Record free cash flow
✔ Dividend increase and share buyback program